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A viable cost-effective and isocratic approach employing C-18 column (250 mm × 4.6 mm, 5 µm) 
based HPLC has been utilized to separate and estimate the drugs, rosuvastatin, amlodipine and their 
stress induced degradation products, simultaneously in pharmaceutical formulations. Focused on ICH 
guideline parameters, the efficient separation of both drugs and their degradation products was achieved 
by optimizing a 30:70 (v/v) solvent mixture of acetonitrile and 0.1 M ammonium acetate buffer (pH 5) 
as mobile phase. The flow rate of the mobile phase was 1.5 mL/min and all the detections were carried 
out at 240 nm using UV detector. The method was linear in the concentration range of 1-200 µg/mL for 
rosuvastatin with 0.996 coefficient of determination value. For amlodipine, linearity was in the range of 
0.5-100 µg/ml with 0.994 coefficient of determination value. Both the drugs along with their degradation 
products were separated in less than twenty minutes. The results of within-day and between-day precision 
were varied from 0.72 to 1.81% for rosuvastatin and 0.83 to 1.88% for amlodipine. The results show that 
this ICH validated method can be employed successfully for the routine as well as stability quantification 
of both the active ingredients simultaneously in pharmaceutical formulations.
Uniterms: High Performance Liquid Chromatography/quantitative analysis. Rosuvastatin/quantitative 
determination. Amlodipine/quantitative determination. Pharmaceutical formulations/quantitative analyis. 
Acetonitrile. UV Detector.
Utilizou-se abordagem de viabilidade custo-efetividade e isocrática, baseada em CLAE, empregando 
coluna C-18 (250 mm x 4,6 mm, 5 µm) para separar e avaliar os fármacos, rosuvastatina, anlodipino e seus 
produtos de degradação induzida por estresse, simultaneamente, em formulações farmacêuticas. Focada 
nos parâmetros das diretrizes da ICH, a separação eficiente de ambos os fármacos e de seus produtos 
de degradação foi obtida por meio da otimização da fase móvel com mistura de solventes 30:70 (v/v), 
respectivamente, acetonitrila e tampão acetato de amônio O,1 M (pH 5). A velocidade de fluxo da fase 
móvel foi de 1,5 mL/min e todas as detecções foram realizadas em 240 nm, utilizando detector de UV. O 
método foi linear no intervalo de concentração de 1-200 µg/mL para a rosuvastatina com coeficiente de 
determinação 0,996. Para o anlodipino, a linearidade ficou na faixa de 0.5-100 µg/mL, com coeficiente 
de determinação 0,994. Ambos os fármacos, junto com seus produtos de degradação, foram separados 
em menos de vinte minutos. Os resultados de precisão intra-dia e inter-dia variaram de 0,72 a 1,81% para 
a rosuvastatina e de 0,83 a 1,88%, para o anlodipino. Os resultados mostram que este método validado 
pelo ICH pode ser empregado com sucesso tanto para a rotina quanto para a quantificação simultânea 
da estabilidade de ambos os ingredientes ativos em formulações farmacêuticas.
Unitermos: Cromatografia Líquida de Alto Desempenho/análise quantitative. Rosuvastatina/determinação 
quantitativa. Anlodipino/determinação quantitativa. Formulações farmacêuticas/análise quantitativa.
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INTRODUCTION
Rosuvastatin [Figure 1A] is the calcium salt 
o f  (E ) -7 - [4 - (4 - f luo ropheny l ) -6 - i sop ropy l -2 -
[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-
3,5-dihydroxyhept-6-enoic acid. It is a competitive 
inhibitor of HMG-CoA reductase (Lennernas, Fager, 1997; 
Nissen et al., 2006), used in the treatment of dyslipidemia 
and hypercholesterolemia (McCormick et al., 2000; 
Olsson, McTaggart, Raza, 2002). Rosuvastatin is very 
effective in reducing low density lipoprotein cholesterol 
and many studies have demonstrated its superiority 
nature over other drugs of its class such as atorvastatin, 
simvastatin and pravastatin (Olsson et al., 2001; Paoletti et 
al., 2001; Davidson et al., 2002). Literature revealed many 
HPLC methods, including stability indicating methods, for 
the separation of rosuvastatin (Mehta et al., 2005; Pandya 
et al., 2010; Gomes et al., 2009; Kaila et al., 2010; Reddy 
et al., 2011; Mostafa et al., 2012; Trivedi, Patel, 2012).
Amlodipine besylate [Figure 1B], chemically 
designated as 2-[(2-aminoethoxy)-methyl]-4-(2-
chlorophenyl) 1,4-dihydro-6-methyl-3,5-pyridine-
dicarboxylic acid-3 ethyl-5 methyl ester, is a calcium 
channel blocker used to treat hypertension and angina 
(Arrowsmith et al., 1986; O` Neil et al., 2006). The drug 
is found to metabolize in the liver and the produced 
metabolites are excreted via urine along with some 
unchanged drug (Abernethy, 1989; Meredith, Elliott, 
1992). Many stability indicating HPLC methods are 
reported in the literature for amlodipine either alone or in 
combination with other active pharmaceutical ingredients 
(Naidu, Kale, Shingare, 2005; Chaudhari, Patel, Shah, 
2007; Mohammadi et al., 2007; Shah et al., 2008; Zaazaa 
et al., 2013; Gumustas, Ozkan, 2013).
The combination of antihyperlipidemic and 
antihypertensive agents is very proficient, as majority of 
hyperlipdemic patients may also have the hypertension 
problems. In order to cope with both the diseases 
simultaneously, a combination comprising of rosuvastatin 
and amlodipine was approved and marketed. This 
combination is available in the commercial market 
on prescription. Literature revealed only two HPLC 
methods for the simultaneous determination of both the 
drugs (Tajane et al., 2012; Banerjee, Vasava, 2013). The 
reported methods although utilized isocratic elution with 
low retention times of both the analytes but they lacks 
stress testing on the drugs and therefore unable to separate 
degradation products. ICH guidelines stress to include 
forced degradation studies in all the developed methods 
including HPLC methods for pharmaceutical formulations 
and they must have stability indicating properties. Keeping 
in view the problem, we focused our attention to develop 
and validate a simple and precise stability indicating 
HPLC method for the concurrent determination of 
rosuvastatin and amlodipine. We are currently engaged in 
binary combination analysis of different classes of drugs 
in pharmaceutical formulations and human plasma (Qutab 
et al., 2007a,b; Qutab et al., 2009; Ashfaq et al., 2007; 
Ashfaq, Khan, Asghar, 2008; Khan et al., 2008, Khan et 
al., 2010; Khan et al., 2013; Khan, Jilani, Ashfaq, 2010; 
Sharif et al., 2010.; Razzaq et al., 2012a,b,c,d; Razzaq 
et al., 2013). The present work is therefore aimed to 
attain the optimum chromatographic conditions for the 
simultaneous determination of rosuvastatin and amlodipine 
in pharmaceutical formulations. The developed method is 
capable to separate both the pharmaceutical components in 
less than twenty minutes and therefore can be proficiently 
utilized in quality control analysis of both drugs and for 
other analytical purposes.
MATERIAL AND METHODS
Chemicals and reagents
Reference standards of both rosuvastatin calcium 
and amlodipine with claimed purity of 99.55% and 
99.06% respectively, were kindly donated by Schazoo 
Zaka Laboratories (Lahore, Pakistan). The combination 
FIGURE 1 - Chemical structures of rosuvastatin calcium (A) and amlodipine besylate (B).
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drug product claimed to contain 10 mg rosuvastatin and 
5 mg amlodipine were purchased from the local market. 
HPLC grade acetonitrile and analytical reagent grade 
other chemicals were purchased from Fluka and were 
used without further purification. Throughout the analysis, 
double distilled water was used. Nylon filters (0.45 mm) 
for mobile phase filtration were from Millipore, USA.
Equipment and chromatographic conditions
Shimadzu LC-20A system (Shimadzu, Japan) 
was used for performing all the experiments including 
development and its subsequent validation. The system 
was equipped with online degasser and auto sampler. 
Detections of both components were performed at 240 nm 
and Class VP HPLC software was used for peak areas 
calculations. Reversed phase discovery C18 column 
(250 × 4.6 mm, 5 µm particle size) was used at room 
temperature. Mobile phase was prepared by mixing 
acetonitrile and 0.1 M ammonium acetate (pH 5.0) in the 
ratio of 30:70 (v/v). Isocratic elution was carried out with 
1.5 mL/min as flow rate of the mobile phase.
Preparation of standard solution
The standard stock solution of rosuvastatin and 
amlodipine was prepared by accurately weighing 50 mg 
of rosuvastatin and 25 mg amlodipine in 50 ml volumetric 
flask, sonicated with few ml of the mobile phase and then 
marked up to point with mobile phase. This provides the 
concentration of rosuvastatin and amlodipine equal to 
1000 µg/mL and 500 µg/mL, respectively. The solutions 
of different concentrations were then prepared by diluting 
the standard stock solution with mobile phase by using the 
dilution formulae.
Preparation of sample solution
Average weight of twenty tablets were taken and 
then ground manually with mortar and pestle. A weighed 
portion of the ground tablets, which was equal to 50 mg 
rosuvastatin and 25 mg amlodipine, was dissolved in 
50 mL of mobile phase. The solution obtained above was 
then further diluted to get desired concentrations.
Linearity
To carry out the linearity, six different concentrations 
of rosuvastatin and amlodipine ranging from 1 µg/mL to 
200 µg/mL (1, 5, 10, 50, 100 and 200 µg/mL) and 0.5 µg/mL 
to 100 µg/mL (0.5, 2.5, 5, 25, 50 and 100 µg/mL), 
respectively, were prepared and analyzed. Triplicate 
analysis of each solution was performed.
Limit of detection (LOD) and limit of 
quantification (LOQ)
For calculating LOQ and LOD of the developed 
method, blank solution and a solution spiked with known 
concentrations of each analyte in decreasing concentration 
were prepared and injected into HPLC system. The LOD 
and LOQ were calculated for both the drugs by measuring 
the minimum level of analytes that can be detected (Signal 
to noise ratio of 3:1) and quantified (Signal to noise ratio 
of 10:1) with accuracy and precision by the system.
Accuracy
For demonstrating accuracy, known amounts of 
rosuvastatin and amlodipine were added into the pre-
analyzed solutions. Theoretical and experimental results 
were then compared. The solutions corresponding to 50, 
100 and 150% of the nominal analytical concentration 
were prepared for this purpose i.e. 50 µg/mL for 
rosuvastatin and 25 µg/mLfor amlodipine.
Precision
For intraday precision, three set of concentrations 
of rosuvastatin and amlodipine were tested five times 
within the same day. From these replicates, percentage 
RSD was calculated. For inter day precision, same samples 
which were used for intraday precision are tested for three 
consecutive days. RSD was then calculated from those.
Robustness
Pre-meditate variations were carried out in the 
experimental conditions of the proposed method to assess 
the method robustness. For this, small variations were 
made in the operating conditions of the method like mobile 
phase composition, flow rate and pH of buffer solution. 
The effect of these changes on chromatographic results 
was then measured.
Forced degradation studies
To carry on forced degradation studies, 2 mL each 
of standard solution was taken in four different 25 mL 
volumetric flasks. All the four flasks were marked as acid, 
base, oxidative and thermal. 2 mL of 5 M HCl was added 
in acid flask, 2 mL 5 M NaOH in basic flask and 1 mL 
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of 6% hydrogen peroxide in oxidative flask were added. 
The thermal flask was remained as such. All the flasks 
except oxidative flask were placed at 60 °C for four hours. 
After completion of stress time, all the three flasks were 
cooled, and acid and base flasks were neutralized using 
appropriate amount of either 5 M HCl or 5 M NaOH. The 
oxidative flask was kept at room temperature for 24 h. All 
the stressed samples were then completed up to the mark 
and analyzed by the proposed method.
RESULTS AND DISCUSSION
The aim of the present research work was to 
develop a sensitive, accurate, isocratic and simple 
HPLC method for the separation and estimation of 
rosuvastatin and amlodipine along with their stress 
induced degradation products. Initially various mobile and 
stationary phases were attempted to accomplish the best 
separation conditions and resolution between rosuvastatin, 
amlodipine and their stress induced degradation products. 
Among all the stationary phases, C-18 stationary phase 
(250 mm × 4.6 mm) was found best for the resolution of 
both the drugs. For the selection of appropriate mobile 
phase composition, acetonitrile was selected along with 
water in different proportions as the start-up mobile phase. 
Different proportions of these two solvents were tried but 
all found unsuitable as good peaks were not obtained. 
The poor peak shapes were expected to be due to the 
lesser polarity of the mobile phase. So in the next phase, 
polarity of the mobile phase was increased by replacing the 
water with ammonium acetate buffer. At 60:40 v/v ratio of 
acetonitrile and ammonium acetate, better peaks for both 
the drugs were obtained but with certain tailing. In order to 
reduce tailing, pH of the ammonium acetate solution was 
varied. For this purpose, 0.1 M ammonium acetate with pH 
equal to 3.0, 5.0 and 7.0 were tried along with acetonitrile 
in 40:60 v/v ratios. Among the three buffer solution, pH 
5.0 was proved to be the best where sharp peaks were 
obtained with acceptable tailing and resolution. When this 
mobile phase composition was applied to analyze samples, 
stressed through acid, base, hydrogen peroxide and heat, 
degradation products produced during the stress, interfered 
the peaks of the active product ingredients. Here both the 
acid and base stressed samples produced co-eluting peak 
of rosuvastatin with the degradation products. Increase 
of organic modifier results either with same results or 
peak of rosuvastatin with some degree of fronting. It was 
then decided to decrease the concentration of organic 
modifier so as to completely separate the degradation 
products from the main peaks. The percentage of organic 
modifier was varied from 60 to 28 percent by decrease 
of 2% each time. The main problem was associated with 
the separation of rosuvastatin from degradation product 
5 (Deg 5 in chromatograms). At 72:28 v/v ratio of buffer 
and acetonitrile, all the degradation products were well 
separated from the main peaks with resolution greater 
than 3 between rosuvastatin and degradation product 5. 
However, the total run time was greater than 30 minutes. 
At 68:32 buffer acetonitrile ratios, separation between 
the above two was not complete and merging of both 
the components was very clear. Finally, 70:30 buffer 
and acetonitrile were chosen as the mobile phase where 
resolution between rosuvastatin and degradation product 
5 was exactly equal to 1.5 with reasonable run time of 
about 20 minutes. By employing the above mentioned 
chromatographic conditions, rosuvastatin and amlodipine 
were separated at retention times of 13.9 and 19.3 min 
respectively [Figure 2].
The developed method was validated using ICH 
prescribed validation parameters such as linearity, 
accuracy, precision, limit of detection and quantification, 
specificity, stability of solutions and robustness. These 
parameters were performed to check the validity of the 
proposed method.
To carry out the linearity, six different concentrations 
of rosuvastatin and amlodipine ranging from 1 µg/mL to 
200 µg/mL (1, 5, 10, 50, 100 and 200 µg/mL) and 0.5 µg/mL 
to 100 µg/mL (0.5, 2.5, 5, 25, 50 and 100 µg/mL), 
respectively, were prepared and analyzed. The calibration 
curves were constructed between concentration on X-axis 
and peak area on Y-axis. The regression equation for the 
rosuvastatin was Y=21604 X + 56856 with value of the 
regression constant or coefficient of determination equal 
to 0.996. The regression equation for amlodipine was 
Y=29444 X + 29461 with value of the regression constant 
or coefficient of determination equal to 0.994. Results 
indicated very good correlation between the concentrations 
and their chromatographic response. The limits of 
detection of an analytical method is the concentration of 
analyte that corresponds to S/N ratio (signal to noise ratio) 
of 3:1. For rosuvastatin and amlodipine that concentration 
corresponds to 0.15 µg/mL and 0.30 µg/mL, respectively, 
where detector gives the desired response with S/N ratio 
3:1. The quantification limit is the lowest concentration 
detected accurately and generally corresponds to the 
detector response with S/N ratio of 10:1 with acceptable 
precision. For rosuvastatin, 1 µg/mL and for amlodipine 
0.5 µg/mL were the concentrations that produce the 
desired response with acceptable accuracy and precision. 
Therefore, LOD was 0.30 µg/mL and 0.15 µg/mL, whereas 
LOQ was 0.5 µg/mL and 1 µg/mLfor rosuvastatin and 
amlodipine, respectively.
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TABLE I - Accuracy of the method
Drug n Level (%) Concentration (µg/mL)
Amount Recovered 
(µg/mL) Recovery (%) RSD (%)
Rosuvastatin
5 50 25.0 24.59 98.36 1.21
5 100 50.0 50.02 100.04 0.99
5 150 75.0 74.05 98.73 0.35
Amlodipine
5 50 12.5 12.39 99.12 1.39
5 100 25.0 24.77 99.08 1.05
5 150 37.5 37.11 98.96 0.67
TABLE II - Intra-day and Inter-day precision of the method
Compound Concentration (µg/mL) Intra-day Precision RSD (%) Inter-day Precision RSD (%)
Rosuvastatin
1.0 1.57 1.81
10.0 1.18 1.59
100.0 0.72 1.13
Amlodipine
0.5 1.49 1.88
5.0 1.12 1.63
50.0 0.83 1.23
FIGURE - 2 Chromatogram of rosuvastatin and amlodipine reference standard.
For demonstrating accuracy, known amounts of 
rosuvastatin and amlodipine were added into the pre-
analyzed solutions. Theoretical and experimental results 
were then compared. The solutions corresponding to 50, 
100 and 150% of the nominal analytical concentrations 
were prepared for this purpose i.e. 50 µg/mL for 
rosuvastatin and 25 µg/mL for amlodipine. From these 
solutions, percentage recovery along with RSD was 
calculated. The results of accuracy are given in Table I.
For intraday precision, three sets of concentrations 
of rosuvastatin and amlodipine were tested five times 
within the same day. For inter day precision, same samples 
which were used for intraday precision were tested for 
three consecutive days. RSD was then calculated from 
both types of data which was less than 2% as shown in 
Table II.
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Pre-meditate variations were carried out in the 
experimental conditions of the proposed method to assess 
the method robustness. For this, faint modifications were 
made in the operating conditions of the method like 
mobile phase composition, flow rate and pH of buffer 
solution. The results showed that slight variations in 
chromatographic conditions had negligible effect on the 
chromatographic parameters. The results of robustness are 
given in Table III and IV.
Forced degradation study was performed on both 
the drugs in order to judge the specificity of the described 
method. Different ICH prescribed stresses like acid, 
base, oxidative and thermal stresses were provided to 
both rosuvastatin and amlodipine in combined form. 
The chromatograms under different stress conditions 
are shown in [Figures 3-5]. Out of the above mentioned 
TABLE III - Robustness study of rosuvastatin
Conditions Assay (%) tR (min) Theoretical Plates Tailing
Acetonitrile: buffer (30:70) 98.89 13.87 12884 1.12
Acetonitrile: buffer (28:72) 99.34 17.23 14114 1.09
Acetonitrile: buffer (32:68) 100.15 10.69 12165 1.15
Flow rate (1.4 mL/min) 100.53 14.86 13009 1.10
Flow rate (1.6 mL/min) 99.29 12.99 12264 1.16
Buffer (pH 5.1) 100.33 13.85 12896  1.13
Buffer (pH 4.9) 100.85 13.88 12784 1.13
TABLE IV - Robustness study of amlodipine
Conditions Assay (%) tR (min) Theoretical Plates Tailing
Acetonitrile: buffer (30:70) 99.78 19.28 16919 1.22
Acetonitrile: buffer (28:72) 100.38 27.56 18612 1.17
Acetonitrile: buffer (32:68) 99.08 15.43 15006 1.30
Flow rate (1.4 mL/min) 100.64 20.66 16812 1.20
Flow rate (1.6 mL/min) 98.79 18.08 17016 1.21
Buffer (pH 5.1) 99.25 19.33 16716 1.22
Buffer (pH 4.9) 99.05 19.30 16707 1.22
FIGURE 3 - Chromatogram of rosuvastatin and amlodipine under acidic stress.
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FIGURE 4 - Chromatogram of rosuvastatin and amlodipine under basic stress.
FIGURE 5 - Chromatogram of rosuvastatin and amlodipine under oxidative stress.
stresses, acidic, basic and oxidative stresses degrade both 
the drugs to some extent whereas thermal stress could not 
produce any degradability to them. Acidic conditions were 
proved to be more damaging where 40% of rosuvastatin 
and about 35% of the amlodipine were degraded. Under 
oxidative stress, the degradation of amlodipine was 
fast compared to rosuvastatin and about 40% of it was 
decomposed in contrast to only 6% of rosuvastatin. Basic 
stress degrades rosuvastatin to about 5% in contrast to 
14% for amlodipine. Thermal stress had no effect on the 
degradability of both the drugs. A number of degradation 
products were also produced during stress testing whose 
chromatographic parameters are shown in Table V.
Application of the proposed method was checked by 
analyzing the rosuvastatin and amlodipine in commercially 
available pharmaceutical products. The results are 
provided in Table VI, which showed high percentage 
recoveries and low RSD (%) values for both analytes.
To check the stability of both components, the 
solution of these components was placed in tight 
containers at room temperature for 48h and their stability 
was checked after each 12 hours period. Results indicate 
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that their percentage recovery remained within the 
acceptable range and no degradation occurred during the 
said period.
CONCLUSION
The present work demonstrates a sensitive and 
reproducible HPLC method for a pharmaceutical 
combination comprising of an anti-hyperlipidemic agent 
along with an anti hypertensive drug. The method is 
highly selective and there was no interference caused 
by any kind of other particles including the degradation 
products produced through forced degradation study. Both 
the drugs and their degradation products were separated 
within twenty minutes. The results of accuracy, linearity, 
precision, LOD, LOQ and specificity indicate that method 
can be used not only for routine analytical analysis but also 
for stability studies for the separation and quantification 
of both rosuvastatin and amlodipine either alone or in 
combination with each other.
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